Plaque Psoriasis study: Deucravacitinib vs Ustekinumab
Official title Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
ClinicalTrials.gov ID: NCT07116967
What this study is testing
What is Deucravacitinib?
An investigational oral medication being studied for plaque psoriasis. It is designed to inhibit a specific enzyme involved in immune signaling.
Also referred to as SOTYKTU.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether Deucravacitinib is as safe as Ustekinumab over a long period for people with plaque psoriasis.
- Who it's for
- You may be able to join if you have plaque psoriasis and are looking for a new treatment option.
- What's involved
- You will receive either Deucravacitinib or Ustekinumab and have regular check‑ins to monitor safety. No special tests beyond routine visits are required.
- Time commitment
- The study lasts many months, with periodic visits to track your health and any side effects.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Deemed by the Investigator to be a candidate for phototherapy or systemic treatment for psoriasis, including ustekinumab;
- Current cigarette smoker
- Diagnosis of hypertension
- Diagnosis of hyperlipidemia
- Diabetes mellitus type 1 or 2
You likely can't join if
- Participants must not have recent history of 1 of the following cardiovascular events: MI, stroke, or coronary revascularization, or VTE within 90...
- Participants must not have unstable CVD, defined as a recent clinical cardiovascular event (eg, unstable angina, rapid atrial fibrillation), or a...
- Participants must not have evidence of active cancer or history of cancer (solid organ or hematologic malignancy including myelodysplastic syndrome)...
- Other protocol define inclusion/exclusion criteria apply.
See the full eligibility criteria
- Deemed by the Investigator to be a candidate for phototherapy or systemic treatment for psoriasis, including ustekinumab;
- Current cigarette smoker
- Diagnosis of hypertension
- Diagnosis of hyperlipidemia
- Diabetes mellitus type 1 or 2
- History of one or more of the following cardiovascular events: Coronary intervention (PCI) or coronary artery bypass grafting (CABG), myocardial infarction (heart attack), cardiac arrest, hospitalization for unstable...
- Obesity
- Family history of premature coronary heart disease or sudden death in a first-degree male relative younger than 55 years of age or in a first-degree female relative younger than 65 years of age.
- Participants must not have recent history of 1 of the following cardiovascular events: MI, stroke, or coronary revascularization, or VTE within 90 days prior to Day 1.
- Participants must not have unstable CVD, defined as a recent clinical cardiovascular event (eg, unstable angina, rapid atrial fibrillation), or a cardiac hospitalization (eg, pacemaker implantation, HF) within 90 days...
- Participants must not have evidence of active cancer or history of cancer (solid organ or hematologic malignancy including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than...
- Other protocol define inclusion/exclusion criteria apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- Tempe, Arizona, United States
- Bentonville, Arkansas, United States
- Rogers, Arkansas, United States
- Encinitas, California, United States
- Encino, California, United States
- Fountain Valley, California, United States
- Fremont, California, United States
- Huntington Beach, California, United States
- Los Angeles, California, United States
- Palmdale, California, United States
- Pasadena, California, United States
- Pomona, California, United States
- Sacramento, California, United States
- Santa Clarita, California, United States
- Santa Monica, California, United States
- Sherman Oaks, California, United States
- Walnut Creek, California, United States
- Castle Rock, Colorado, United States
+ 251 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; Scottsdale, Arizona, United States; Tempe, Arizona, United States; Bentonville, Arkansas, United States; Rogers, Arkansas, United States; Encinitas, California, United States and 265 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.